Articles tagged with Cancer Cells
Researchers identified how AML cells develop resistance to first-line treatments by up-regulating multiple signalling pathways. Targeting RAS family proteins shuts off this route, preventing cancer cell death.
Researchers developed a breakthrough test to assess the enzymatic activity of glutathione peroxidase 4 (GPX4), a pivotal regulator of ferroptosis. The assay accurately measures GPX4 activity and extends its utility beyond GPX4, allowing for precise evaluation of other enzymes involved in ferroptosis regulation.
Researchers at Tel Aviv University developed a novel therapeutic strategy using existing medications to inhibit bone metastasis in breast cancer patients. The combination of drugs improved survival rates and reduced bone metastases in animal models and human tissue samples.
A study published in Nature Genetics reveals early cell changes in healthy carriers of BRCA1 and BRCA2 gene mutations, suggesting a potential target for breast cancer prevention. The researchers created the world's largest catalogue of human breast cells, which may lead to the use of existing immunotherapy drugs as an early intervention.
Researchers at the University of Toronto have found that two enzymes, APOBEC3C and APOBEC3D, promote resistance to chemotherapy drug gemcitabine in pancreatic cancer cells. Removing these enzymes can kill cancer cells by stymieing DNA repair.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
Researchers have discovered a new immunotherapy approach to overcome resistant leukemia by targeting the mutated TP53 gene. Combining pharmacological therapies with genetically engineered CAR T-cells increases effectiveness against cancer cells, offering promising strategies for patients with resistant disease.
A UNIGE team has identified the mechanism of action of PARP inhibitors, used to treat breast and ovarian cancer. By blocking one activity while preserving another, these inhibitors can maintain toxic effects on cancer cells while sparing healthy cells.
Scientists synthesized major component of mucus and discovered that altering healthy cell mucins made them act more like cancer cells. Researchers created synthetic mucins to study their impact on cancer biology, finding a potential target for cancer treatments.
Cancer cells can adapt to low oxygen levels by increasing glycolysis, a process controlled by enzymes LDHA and GOT1. Inhibiting these enzymes could target hard-to-reach cancer cells without affecting healthy cells.
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
Researchers have deciphered trabectedin's precise mechanism of action, revealing its ability to induce persistent DNA breaks in cancer cells. This disruption of the transcription-coupled nucleotide excision repair (TC-NER) pathway leads to long-lasting DNA breaks that ultimately kill cancer cells.
Human type 2 innate lymphoid cells have been found to attack and kill cancer cells in human models, with the ability to be expanded and applied in larger numbers to overpower tumors. This breakthrough could lead to a new therapeutic approach using these cells as an 'off-the-shelf' product.
Researchers discovered that lung cancer cells can persist in the presence of cigarette smoke due to a protein pump called ABCG2, which clears damaging molecules from the cells. This mechanism could also contribute to resistance to pharmaceutical treatments in cancer cells.
Research reveals micro- and nanoplastics can persist in the human body for longer than previously thought, being passed on to newly formed cells during cell division. The study also suggests these tiny plastic particles may promote the spread of cancer by increasing tumor migration.
A study published in Cancer Research Communications reveals a potential genetic marker associated with better survival outcomes in patients with head and neck cancer. The researchers found that the presence of a specific genetic variant and higher expression of the GAN gene product gigaxonin may contribute to improved survival rates.
A new nanocarrier has been developed that can selectively release drugs in cancer cells through controlled endosomal escape. The approach exploits the unique enzymatic activity of cancer cells, allowing for targeted delivery and reduced harm to healthy cells.
Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.
A recent study used AI trained on cell-to-cell communication networks to predict drug responsiveness in immunotherapy for cancer. The model demonstrated high accuracy in analyzing samples from 700 patients with four types of cancer, identifying key communication pathways related to responsiveness and resistance.
USC researchers have designed nanoparticles that can target and highlight cancer cells in lymph nodes, allowing for earlier detection of metastasis. The particles work by hitchhiking on immune cells to reach the lymph nodes, where they can amplify the signal detected by MRI scans.
Researchers identified a group of proteins that help cancer cells maintain genetic stability and avoid immune system detection. By depleting these proteins, they triggered an inflammatory response and made the cancer cells visible to the immune system.
Researchers have engineered T cells with a mutation found in malignant lymphoma cells, making them more than 100 times potent at killing cancer cells. The new approach shows promise against solid tumors and could provide long-term immunity against cancer.
Scientists at Northwestern University and UCSF have developed a new technique to enhance the potency of human T cells against cancer. By studying mutations in malignant T cells, they were able to create T cells that can kill tumors derived from skin, lung, and stomach cancers in mice.
Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.
Scientists at City of Hope discovered a new cellular mechanism that plays a key role in cancer cells' ability to cause disease. The study identified integrin αV and β5 as crucial proteins that partner to spur cancer cell growth, offering a promising target for new therapies.
Researchers discovered that depletion of the protein DPYSL5 can restore drug-responsive neuroendocrine prostate cancer cells, promoting cell transformation and lineage plasticity. This finding could lead to the development of new cancer drugs.
A low-cost, DIY device using a coin-vibrating motor has been developed to rapidly generate uniform tumor spheroids. These 3D tumor models exhibit clinically typical responses to chemotherapy and can help overcome limitations of traditional cell cultures.
Researchers at the University of Oklahoma Health Sciences have developed a new imaging technique that can detect pancreatic cancer cells approximately 10 times more magnificently than current options. The approach combines contrast agent recognition with Multispectral Optoacoustic Tomography, enabling real-time detection and surgery pl...
A new CRISPR-based technology, TRED-I, has been developed to increase visibility of cancer cells to the immune system by augmenting MHC class I molecules. This technology has shown promising results in animal cancer models, reducing tumor sizes and enhancing treatment efficacy when used with existing immunotherapy.
Researchers studied how epithelial cells sense small changes in their environment using ion channels. They found that even small movements can trigger rapid intracellular calcium changes via mechanosensitive cation channels, which play a key role in touch sensation and other physiological functions.
A recent study published in Cell Reports reveals that cancer cells can prevent the immune system from attacking them by inhibiting key checkpoints. Researchers found that monotherapy agents targeting these checkpoints may not be effective without an inflammatory trigger, explaining why some immunotherapies work while others fail.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
A new study published in Oncogene highlights the effectiveness of MDX-124, a therapeutic drug targeting annexin-A1, which promotes tumour progression. High annexin-A1 expression levels correlate with poorer overall survival in various cancers.
Researchers developed a new photosensitizer, polphylipoprotein (PLP), to improve photodynamic therapy (PDT) efficacy. PLP selectively induces necrosis in cancer cells by exploiting the autophagy mechanism under starvation, leading to high selectivity and potential efficacy.
Sezáry syndrome patients face a vicious circle where cancer and treatment weaken the immune system, allowing bacteria like S. aureus to thrive. Eliminating these bacteria may make cancer cells more susceptible to anti-cancer drugs.
A systematic analysis of cancer cells identifies 370 candidate priority drug targets across 27 cancer types. Researchers used machine learning methods to find promising targets and linked them to specific biological markers and genetic features.
A team of scientists has identified a previously unrecognized control point in DNA repair processes, which could lead to novel cancer therapies by inhibiting the repair of damaged cancer cells. The newly discovered GSE1-CoREST complex contains three enzymes that control DNA repair and may form the basis for improved cancer treatments.
Researchers have found a way to control MYC's hyperactivity using a peptide compound with sub-micro-molar affinity. This breakthrough offers hope for more effective treatments for cancer patients.
Researchers found that a rare type of T cell, Vd1-gd T cells, can predict patient response to immunotherapy treatments. The presence of these cells is highly predictive of positive responses in cancers with few mutations, and they may be more resistant to suppression from cancer cells.
Researchers have developed nanodrones that target and eliminate cancer cells by recruiting natural killer cells to tumor sites. The study offers a potential solution for intractable types of cancers, with promising results in suppressing tumor growth without causing side effects.
Researchers have developed a novel method to produce a selective anticancer precursor substance. The synthesis involves the reaction of metal-active oxygen species with nitrile, utilizing cost-effective metals at lower temperatures. This breakthrough opens up new possibilities in developing innovative drugs against cancer.
Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available
A new study found that removing the RUNX1 transcription factor and its target gene can lead to a network collapse, causing cancer cell death in a type of aggressive leukemia. This breakthrough identifies specific protein targets for potential treatments.
Researchers developed a novel cancer sensor using viral enhancement and nanomaterials, achieving ultra-high sensitivity in detecting breast cancer cells. The new P-DBS technology outperformed existing electrical-based sensors in terms of sensitivity and signal contrast.
Researchers at the University of Gothenburg have developed a way to distinguish different types of structural changes in glycan molecules linked to various cancers. The AI-enhanced method uses mass spectrometry to identify patterns in data sets, providing a precise answer to what will change for a specific disease.
Researchers explore the properties of cytostatic persisters in cancer treatment, highlighting their therapeutic potential and challenges. The study suggests that targeting these persisters before resistance emerges can reduce cancer recurrence.
Researchers at Mass General Brigham have developed a new class of proteasome inhibitors that specifically target the β2 active site in cancer cells. The newly synthesized compounds effectively inhibit multiple myeloma cell growth and show promise for reducing therapeutic resistance and side effects when combined with existing drugs.
The Tokyo University of Science team has created a device that enables the simultaneous evaluation of many cancer cells, allowing for rapid and accurate analysis. The system, called cROT, increases throughput to 2,700 cells per hour, making it more than 100 times faster than traditional methods.
A new study from Indian Institute of Science finds that certain types of cancer cells respond well to IFN-γ activation, while others don't. The researchers suggest approaches to make non-responsive cancer cells better respond to immunotherapy by targeting their metabolism.
A new study in mice shows that a hybrid treatment combining a drug and a protein fragment can prevent the growth of blood cancer cells by targeting the RAS gene mutation. The treatment, which blocks cell division and multiplication, has shown promising results in live animals with multiple myeloma tumors.
Researchers at the University of Turku found that bexmarilimab therapy alters macrophage behavior to promote anti-tumor immune defense. The therapy was well-tolerated and stabilized disease progression in patients with advanced-stage cancer, inducing tumor-associated macrophage and lymphocyte activation.
A new study found that a type of white blood cell called tumour-associated macrophages can promote the formation of lymphatic vessels, facilitating cancer cell transport to other organs. However, these cells also reduce breast cancer spread to the lungs while increasing it to the lymph nodes.
Researchers discovered that Osteopontin induces mitochondrial biogenesis in deadherent breast tumor cells, which aids metastatic success. The study suggests a possible mechanism and targets for treating cancer metastasis by increasing ATP levels and mitochondrial mass.
Researchers Haval Shirwan and Esma Yolcu design a molecule, SA-4-1BBL, that mobilizes immune cells to target cancer cells. The molecule shows promising results in preventing lung cancer by triggering the immune system's defense mechanism.
Researchers developed GraphNovo, a program that provides accurate understanding of peptide sequences in cells, improving immunotherapy for unique cases. The AI model enhances de novo peptide sequencing accuracy, filling gaps with precise mass data.
Researchers discovered an alternative immune response involving NK and CD4+ T cells that can recognize and attack cancer cells when the usual recognition marker B2M is missing. This finding holds potential for developing more effective combination cancer immunotherapy treatments.
A new study by Tulane University has identified a previously unknown molecular pathway that could halt lung cancer growth. The research found that protein RBM10 can suppress lung cancer by targeting the function of c-Myc, a protein that drives cancer cell growth and proliferation.
Researchers at Duke University have developed a new computational model called Adaptive Physics Refinement (APR) that can simulate the movement of individual cancer cells across long distances within the entire human body. This approach captures detailed cellular interactions and their effects on cellular trajectory, providing valuable...
Researchers found that cancer cells are more vulnerable to radiotherapy when using the less common 'YC' first-base-cytosine site instead of the usual 'YR' adenine or guanine start sites. This discovery enables further understanding of gene regulation in cancers and potential targets for treatment.
Researchers at the University of Pennsylvania School of Medicine found that lidocaine activates the bitter taste receptor T2R14, which triggers apoptosis in cancer cells. This mechanism could lead to improved treatment options for patients with head and neck cancers, particularly those associated with human papillomavirus.